Xylem (NYSE:XYL) Price Target Lowered to $152.00 at UBS Group

Key Points

• UBS cut its price target on Xylem to $152 (from $155) while keeping a "buy" rating, implying about a 17.3% upside from the current share price.
• Several other analysts also trimmed targets this week, leaving a MarketBeat consensus rating of "Moderate Buy" and a consensus price target near $155.31.
• Xylem shares traded around $129.57 after reporting Q EPS of $1.42 (in line with estimates) and revenue up 6.3% YoY, and the company authorized a $1.5 billion buyback (up to ~4.8% of shares).

Xylem (NYSE:XYL - Get Free Report) had its price target lowered by investment analysts at UBS Group from $155.00 to $152.00 in a report released on Thursday,Benzinga reports. The firm currently has a "buy" rating on the industrial products company's stock. UBS Group's price objective indicates a potential upside of 17.31% from the company's current price.

XYL has been the topic of several other research reports. Stifel Nicolaus dropped their price target on shares of Xylem from $178.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, February 11th. Mizuho set a $138.00 price target on shares of Xylem in a research note on Wednesday, February 11th. Royal Bank Of Canada dropped their price target on shares of Xylem from $176.00 to $162.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 11th. Citigroup dropped their price target on shares of Xylem from $182.00 to $174.00 and set a "buy" rating on the stock in a research note on Wednesday, February 11th. Finally, William Blair assumed coverage on shares of Xylem in a research note on Monday, January 26th. They set an "outperform" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $155.31.

Xylem Stock Up 1.3%

Xylem stock traded up $1.60 during trading hours on Thursday, hitting $129.57. The company had a trading volume of 2,303,585 shares, compared to its average volume of 1,921,745. The firm has a market capitalization of $31.50 billion, a P/E ratio of 33.05, a price-to-earnings-growth ratio of 1.74 and a beta of 1.18. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.62 and a quick ratio of 1.28. The firm's fifty day moving average is $126.74 and its 200-day moving average is $137.35. Xylem has a fifty-two week low of $104.14 and a fifty-two week high of $154.27.

Xylem (NYSE:XYL - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The industrial products company reported $1.42 earnings per share for the quarter, meeting the consensus estimate of $1.42. Xylem had a net margin of 10.59% and a return on equity of 11.11%. During the same period last year, the firm posted $1.18 EPS. The company's revenue for the quarter was up 6.3% compared to the same quarter last year. Xylem has set its FY 2026 guidance at 5.350-5.560 EPS. On average, research analysts forecast that Xylem will post 4.65 earnings per share for the current year.

Xylem declared that its board has initiated a share repurchase plan on Wednesday, February 25th that permits the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization permits the industrial products company to repurchase up to 4.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in Xylem by 14.4% in the 1st quarter. AQR Capital Management LLC now owns 30,955 shares of the industrial products company's stock valued at $3,645,000 after purchasing an additional 3,900 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Xylem by 3.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,151 shares of the industrial products company's stock worth $496,000 after acquiring an additional 132 shares during the period. Empowered Funds LLC lifted its holdings in shares of Xylem by 56.1% during the 1st quarter. Empowered Funds LLC now owns 8,678 shares of the industrial products company's stock worth $1,037,000 after acquiring an additional 3,120 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Xylem by 97.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,151 shares of the industrial products company's stock worth $1,442,000 after acquiring an additional 5,509 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Xylem by 114.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,192 shares of the industrial products company's stock worth $154,000 after acquiring an additional 635 shares during the period. 87.96% of the stock is currently owned by institutional investors and hedge funds.

About Xylem

Xylem Inc NYSE: XYL is a global water technology company that designs, manufactures and services engineered systems and equipment for the transport, treatment, testing and efficient use of water. Its product portfolio spans pumps and pumping systems, valves, filtration and disinfection equipment, sensors and analytical instruments, and digital solutions for monitoring and control of water infrastructure. Xylem serves the full water cycle with offerings for water and wastewater utilities, industrial customers, commercial and residential buildings, and agricultural applications.

The company was established as an independent publicly traded company in 2011 following a corporate spin-off from ITT Corporation and is headquartered in Rye Brook, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.